Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for LUPIN
Revenue projections for LUPIN

Investors may react cautiously to news that Lupin Limited's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.00000
forwardPE 22.78436
debtToEquity 31.51300
earningsGrowth 0.37300
revenueGrowth 0.24300
grossMargins 0.70556
operatingMargins 0.26460
trailingEps 101.43000
forwardEps 97.40891

Lupin Limited's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
Lupin Limited's positive earnings and revenue growth reflect an optimistic outlook for the company's future. The growth in these key areas indicates that Lupin Limited is expected to continue expanding its business and boosting its financial performance in the coming periods.
LUPIN's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
Lupin Limited's forward EPS is lower than its trailing EPS, indicating the company may experience reduced profitability. This signals that the company's earnings growth could slow down in the near future.

Price projections:

Price projections for LUPIN
Price projections for LUPIN

LUPIN's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about LUPIN's ability to grow.

Recommendation changes over time:

Recommendations trend for LUPIN
Recommendations trend for LUPIN


With analysts showing a buy bias for Lupin Limited, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning Lupin Limited as a safe and profitable place for investors to allocate their funds and seek growth.